VSTM Share Price

Open 1.10 Change Price %
High 1.14 1 Day 0.01 0.90
Low 1.10 1 Week -0.05 -4.27
Close 1.12 1 Month -0.01 -0.88
Volume 104499 1 Year -0.97 -46.41
52 Week High 2.09
52 Week Low 0.00
VSTM Important Levels
Resistance 2 1.16
Resistance 1 1.14
Pivot 1.12
Support 1 1.10
Support 2 1.08
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.70 0.20%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
RITT 0.06 -45.45%
DVOX 0.05 -44.44%
More..

Verastem, Inc. (NASDAQ: VSTM)

VSTM Technical Analysis 5
As on 2nd Dec 2016 VSTM Share Price closed @ 1.12 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.37 & Strong Sell for SHORT-TERM with Stoploss of 1.30 we also expect STOCK to react on Following IMPORTANT LEVELS.
VSTM Target for December
1st Target up-side 1.27
2nd Target up-side 1.35
3rd Target up-side 1.44
1st Target down-side 1.01
2nd Target down-side 0.93
3rd Target down-side 0.84
VSTM Other Details
Segment EQ
Market Capital 171709120.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.verastem.com
VSTM Address
VSTM
215 First Street
Suite 440
Cambridge, MA 02142
United States
Phone: 617-252-9300
Interactive Technical Analysis Chart Verastem, Inc. ( VSTM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Verastem, Inc.
VSTM Business Profile
Verastem, Inc. is a clinical biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. The Company also develops companion diagnostics. The Company has technology to create a stable population of cancer stem cells that it uses to screen for and identify small molecule compounds that target cancer stem cells. The Company�s advanced programs target the Focal Adhesion Kinase (FAK), and the PI3K/mTOR signaling pathways. The Company�s lead FAK inhibitor, VS-6063, is in Phase 1/1b testing in ovarian cancer. The Company�s solution is to discover and develop an oncology therapeutics targeting CSCs along with companion diagnostics. The Company is focused on the discovery and development of small molecules to allow flexibility in the design of molecules for optimized efficacy and safety primarily as orally available drug candidates.